Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of an Alum-adjuvanted Inactivated H7N9 Influenza Vaccine: a Randomized, Blind, Placebo-controlled, a Phase II Clinical Trial

NCT03755427 is registered in ClinicalTrials.gov with Shanghai Institute Of Biological Products as lead sponsor.

NCT NCT03755427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03755427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of an Alum-adjuvanted Inactivated H7N9 Influenza Vaccine: a Randomized, Blind, Placebo-controlled, a Phase II Clinical Trial
Lead sponsor
Shanghai Institute Of Biological Products
Phase
Phase 2
Overall status
Completed
Start date
November 10, 2018
Completion date
November 15, 2019
Enrollment
560 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

h7n9 influenza